IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo

Inflammatory Bowel Diseases

Volumn 17, Issue 6, 2011, Pages 1343-1358

  Mudter, Jonas ^a   Yu, Jingling ^b   Zufferey, Christel ^c   Brüstle, Anne ^d   Wirtz, Stefan ^a   Weigmann, Benno ^a   Hoffman, Arthur ^b   Schenk, Mirjam ^d   Galle, Peter R ^c   Lehr, Hans A ^e   Mueller, Christoph ^c   Lohoff, Michael ^d   Neurath, Markus F ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Crohn's disease; endoscopy; IL 17; IL 6; inflammatory bowel disease; Interferon regulatory factor 4; T cells

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYTOKINE; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 6; MESSENGER RNA; REGULATOR PROTEIN; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SALICYLIC ACID DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; COLITIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; EXPERIMENTAL COLITIS; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; MALE; MOUSE; MUCOSA CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROVIRUS INFECTION; T CELL DEPENDENT TRANSFER COLITIS; TH17 CELL; ULCERATIVE COLITIS; WILD TYPE;

ADULT; ANIMALS; COLITIS; COLITIS, ULCERATIVE; CROHN DISEASE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON REGULATORY FACTORS; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MICE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; TH17 CELLS;

EID: 79955835559     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21476     Document Type: Article

References (38)

1. Shanahan F, Bernstein CN,. The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol. 2009; 25: 301-305.
2. Abraham C, Cho JH,. Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066-2078.
3. Strober W, Fuss IJ, Blumberg RS,. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002; 20: 495-549. (Pubitemid 34293433)
4. Blumberg RS, Saubermann LJ, Strober W,. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol. 1999; 11: 648-656.
5. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996; 157: 1261-1270. (Pubitemid 126449643)
6. Rose-John S, Mitsuyama K, Matsumoto S, et al. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des. 2009; 15: 2095-2103.
7. Mudter J, Wirtz S, Galle PR, et al. A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis. Pathobiology. 2002; 70: 170-176. (Pubitemid 36184451)
8. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. 2000; 6: 583-588. (Pubitemid 30305911)
9. Yamamoto M, Yoshizaki K, Kishimoto T, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol. 2000; 164: 4878-4882. (Pubitemid 30238092)
10. Kai Y, Takahashi I, Ishikawa H, et al. Colitis in mice lacking the common cytokine receptor gamma chain is mediated by IL-6-producing CD4+ T cells. Gastroenterology. 2005; 128: 922-934. (Pubitemid 40523544)
11. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active crohn's disease. Gastroenterology. 2004; 126: 989-996. (Pubitemid 38451170)
12. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity. 2007; 27: 660-669. (Pubitemid 47615504)
13. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006; 116: 1310-1316.
14. Brustle A, Heink S, Huber M, et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol. 2007; 8: 958-966. (Pubitemid 47300010)
15. Brass AL, Zhu AQ, Singh H,. Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers. EMBO J. 1999; 18: 977-991. (Pubitemid 29082277)
16. Rengarajan J, Mowen KA, McBride KD, et al. Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med. 2002; 195: 1003-1012. (Pubitemid 34412002)
17. Mudter J, Amoussina L, Schenk M, et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest. 2008; 118: 2415-2426. (Pubitemid 351949770)
18. Kaser A, Blumberg RS,. Adaptive immunity in inflammatory bowel disease: state of the art. Curr Opin Gastroenterol. 2008; 24: 455-461.
19. Morrissey PJ, Charrier K, Braddy S, et al. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med. 1993; 178: 237-244. (Pubitemid 23173259)
20. Powrie F, Leach MW, Mauze S, et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993; 5: 1461-1471. (Pubitemid 23325202)
21. Wirtz S, Becker C, Blumberg R, et al. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol. 2002; 168: 411-420. (Pubitemid 34014143)
22. Weigmann B, Tubbe I, Seidel D, et al. Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. Nat Protoc. 2007; 2: 2307-2311.
23. Lohoff M, Mak TW,. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol. 2005; 5: 125-135. (Pubitemid 40208902)
24. Watanabe T, Asano N, Murray PJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008; 118: 545-559. (Pubitemid 351206545)
25. Fouser LA, Wright JF, Dunussi-Joannopoulos K, et al. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev. 2008; 226: 87-102.
26. Sundrud MS, Rao A,. Regulation of T helper 17 differentiation by orphan nuclear receptors: it's not just ROR gamma t anymore. Immunity. 2008; 28: 5-7.
27. Chen Q, Yang W, Gupta S, et al. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity. 2008; 29: 899-911.
28. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003; 52: 65-70. (Pubitemid 36020767)
29. Nielsen OH, Kirman I, Rudiger N, et al. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol. 2003; 38: 180-185. (Pubitemid 36349930)
30. Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut. 2008; 57: 1682-1689.
31. Dambacher J, Beigel F, Zitzmann K, et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 2009; 58: 1207-1217.
32. Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology. 2008; 134: 1038-1048.
33. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009; 58: 1629-1636.
34. Lee JH, Cho ML, Kim JI, et al. Interleukin 17 (IL-17) increases the expression of toll-like receptor-2, 4, and 9 by increasing IL-1{beta} and IL-6 production in autoimmune arthritis. J Rheumatol. 2009; 36: 684-692.
35. Kimura A, Naka T, Kishimoto T,. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci U S A. 2007; 104: 12099-120104.
36. Mudter J, Neurath MF,. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis. 2007; 13: 1016-1023. (Pubitemid 47309974)
37. Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity. 2008; 29: 628-636.
38. Leppkes M, Becker C, Ivanov II, et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 2009; 136: 257-267.